27-Feb-2026
Iovance Biotherapeutics to Present at Upcoming Conferences
Globe Newswire (Thu, 26-Feb 8:00 AM ET)
TipRanks (Thu, 26-Feb 4:50 AM ET)
Iovance Biotherapeutics Delivers 30% Quarterly Revenue Growth and Achieves Key Clinical Milestones
Market Chameleon (Wed, 25-Feb 6:17 AM ET)
TipRanks (Wed, 25-Feb 8:10 AM ET)
Barclays Remains a Buy on Iovance Biotherapeutics (IOVA)
TipRanks (Wed, 25-Feb 4:56 AM ET)
Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
Benzinga (Tue, 24-Feb 2:14 PM ET)
TipRanks (Tue, 24-Feb 1:45 PM ET)
Seeking Alpha News (Tue, 24-Feb 12:58 PM ET)
Iovance surges on Q4 results, Amtagvi data in soft tissue sarcoma
Seeking Alpha News (Tue, 24-Feb 11:43 AM ET)
TipRanks (Tue, 24-Feb 11:30 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of February 27, 2026, IOVA stock price climbed to $3.86 with 18,191,175 million shares trading.
IOVA has a beta of 1.71, meaning it tends to be more sensitive to market movements. IOVA has a correlation of 0.06 to the broad based SPY ETF.
IOVA has a market cap of $1.40 billion. This is considered a Small Cap stock.
Last quarter Iovance Biotherapeutics reported $87 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.01.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): XBI, VTI, IWM, VB, IWN.
IOVA has underperformed the market in the last year with a return of -26.6%, while SPY returned +18.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in IOVA shares. However, IOVA has outperformed the market in the last 3 month and 2 week periods, returning +58.2% and +50.2%, while SPY returned +1.2% and +0.6%, respectively. This indicates IOVA has been having a stronger performance recently.
IOVA support price is $3.56 and resistance is $4.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.